Key result
Novel oral anticoagulants, including rivaroxaban, apixaban, and dabigatran etexilate, show promising results for postoperative thromboprophylaxis in hip- or knee-replacement surgery.
Novel oral anticoagulants offer promising efficacy and convenience for perioperative thromboprophylaxis, though their broader impact will depend on the balance of safety, efficacy, and cost-effectiveness.
No takes yet. Share an insight, caveat, or question.
May support NOAC thromboprophylaxis after hip/knee replacement; leaves open broader perioperative roles and cost-effectiveness.
Levy et al. (2010) conducted a review in Patients undergoing surgery requiring anticoagulation. Novel oral anticoagulants (rivaroxaban, apixaban, dabigatran etexilate) was evaluated. Novel oral anticoagulants, including rivaroxaban, apixaban, and dabigatran etexilate, show promising results for postoperative thromboprophylaxis in hip- or knee-replacement surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: